Proceedings · Session S-450 · filed November 17, 2026
Research Funding & PolicySession paper
173 countries now have AMR plans, but only 22% fund them fully
WHO's 2026 TrACSS survey of 183 countries finds 173 with AMR plans, but only 22% fully funded; one in six confirmed bacterial infections resisted antibiotics in 2023.
By Tom Whitfield3 min read510 words
Summary
- 173 countries have national AMR plans, up from 79 in 2017, but only 22% report full funding and implementation.
- One in six laboratory-confirmed bacterial infections worldwide was antibiotic-resistant in 2023.
- Only 36% of countries have national reference laboratories for bacterial and fungal testing, against an 80% target for 2030.
- The 2026 TrACSS survey covered 183 countries, 94% of WHO Member States.
- WHO released two new tools under its AMR Diagnostic Initiative: a prioritised test catalogue and clinical lab guidance.

Only 22% of countries report having the funding to fully implement their national antimicrobial resistance (AMR) action plans — despite 173 of them now having such plans on paper. That figure comes from the World Health Organisation's latest Tracking Antimicrobial Resistance Country Self-assessment Survey (TrACSS), released Monday ahead of World AMR Awareness Week.
The 2026 survey drew responses from 183 countries, covering 94% of WHO Member States. The headline trend looks positive: countries with AMR plans have more than doubled, from 79 in 2017 to 173 today. The funding reality does not match. WHO says the gap leaves patients exposed to drug-resistant infections worldwide.
How bad is the resistance problem?
The scale is measurable. In 2023, approximately one in six laboratory-confirmed bacterial infections worldwide was resistant to antibiotics, according to WHO. That makes common infections increasingly difficult to treat.
The consequences reach beyond infectious disease wards. WHO warns that AMR raises the risk of routine medical procedures — surgery, childbirth, cancer treatment — because medicines increasingly fail against resistant microorganisms.
What did WHO's Director-General say?
WHO Director-General Dr Tedros Ghebreyesus said national plans are essential to protecting medicines, but stressed that countries must translate commitments into action through adequate investments. He called for increased investment in four areas:
- infection prevention
- surveillance
- equitable access to essential antimicrobials
- quality diagnostics
The point about diagnostics is where the data gets uncomfortable.
How large is the diagnostic gap?
Only 36% of countries have national reference laboratories equipped to test selected bacteria and fungi. WHO's global target, set for 2030, is that 80% of countries have comprehensive bacterial and fungal resistance testing capacity. The current figure falls well short.
The consequences are practical. Inadequate diagnostic testing means patients can receive ineffective or unnecessary antibiotics, while resistant infections and outbreaks may go undetected.
Two further survey findings sketch the implementation picture:
- 63% of countries have guidelines for appropriate antimicrobial use
- Slightly more than half have surveillance systems monitoring antibiotic consumption and resistance levels
What tools is WHO deploying?
To address the gaps, WHO has introduced two practical tools under its AMR Diagnostic Initiative. One provides a prioritised catalogue of diagnostic tests; the other offers guidance for clinical laboratories.
Both aim to strengthen laboratories' capacity to diagnose bacterial and fungal infections, supporting timely detection and appropriate treatment of drug-resistant diseases. For lab managers and public health procurement teams, the catalogue approach signals where WHO sees the highest-value test categories — a useful reference point when budgets force prioritisation.
What happens next?
World AMR Awareness Week runs from 18 to 24 November. The 2026 campaign carries the theme "One Health, one action: Prevent AMR now", highlighting the interconnected health of humans, animals, plants and the environment.
Ghebreyesus called on governments, farmers, veterinarians, environmental experts and communities to strengthen collective efforts against antimicrobial resistance.
The survey numbers frame the challenge ahead: a near-universal paper commitment, one in five countries funded to deliver it, and a diagnostic base covering barely a third of member states — with 2030 targets now four budget cycles away.
via businessday.ng (Source)
Filed under
- antimicrobial-resistance
- amr-action-plans
- diagnostic-capacity
- tracss
- one-health
More from Tom Whitfield
Show full bio
Senior reporter covering technology and product news in research and development at Hypothesis Wire.
268 articles
References
- UN Panel Aims to Reset How Evidence Reaches AMR Policymakers
- Global health R&D funding falls 12% as donors warn of PDP 'natural selection'
- South Africa's R&D Faces R2.5bn Hole as US Funding Pullout Reshapes STI Financing
- 2026 Access to Medicine Index: Africa's Three Biggest Markets Left Off Access Plans
- Nigerian Trust in Science Stalls at 15 Per Cent, 11 Points Below 2018